214 related articles for article (PubMed ID: 25682035)
21. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
22. GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation.
Poirier S; Mamarbachi M; Chen WT; Lee AS; Mayer G
Cell Rep; 2015 Dec; 13(10):2064-71. PubMed ID: 26628375
[TBL] [Abstract][Full Text] [Related]
23. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.
Ai D; Chen C; Han S; Ganda A; Murphy AJ; Haeusler R; Thorp E; Accili D; Horton JD; Tall AR
J Clin Invest; 2012 Apr; 122(4):1262-70. PubMed ID: 22426206
[TBL] [Abstract][Full Text] [Related]
24. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
[TBL] [Abstract][Full Text] [Related]
25. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
[TBL] [Abstract][Full Text] [Related]
26. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
[TBL] [Abstract][Full Text] [Related]
27. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
Dong B; Singh AB; Shende VR; Liu J
Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
[TBL] [Abstract][Full Text] [Related]
28. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis.
Alvarez ML; Khosroheidari M; Eddy E; Done SC
Atherosclerosis; 2015 Oct; 242(2):595-604. PubMed ID: 26318398
[TBL] [Abstract][Full Text] [Related]
30. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
Shende VR; Wu M; Singh AB; Dong B; Kan CF; Liu J
J Lipid Res; 2015 Apr; 56(4):801-9. PubMed ID: 25652089
[TBL] [Abstract][Full Text] [Related]
31. Targeting PCSK9 for the treatment of hypercholesterolemia.
Hedrick JA
Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
[TBL] [Abstract][Full Text] [Related]
32. Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation.
Xiao HB; Sun ZL; Zhang HB; Zhang DS
Pharmacol Rep; 2012; 64(4):889-95. PubMed ID: 23087140
[TBL] [Abstract][Full Text] [Related]
33. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
34. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.
Cao A; Wu M; Li H; Liu J
J Lipid Res; 2011 Mar; 52(3):518-30. PubMed ID: 21196532
[TBL] [Abstract][Full Text] [Related]
35. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
[TBL] [Abstract][Full Text] [Related]
36. Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation.
Abdelwahed KS; Siddique AB; Ebrahim HY; Qusa MH; Mudhish EA; Rad AH; Zerfaoui M; Abd Elmageed ZY; El Sayed KA
Mar Drugs; 2023 Mar; 21(4):. PubMed ID: 37103355
[TBL] [Abstract][Full Text] [Related]
37. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
Tavori H; Rashid S; Fazio S
Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
[TBL] [Abstract][Full Text] [Related]
38. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
[TBL] [Abstract][Full Text] [Related]
39. Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
Grefhorst A; McNutt MC; Lagace TA; Horton JD
J Lipid Res; 2008 Jun; 49(6):1303-11. PubMed ID: 18354138
[TBL] [Abstract][Full Text] [Related]
40. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
